F S&P 500
5,098.75 -5.25 (-0.10%) F Dow Jones
37,949.00 -44.00 (-0.12%) F Nasdaq
17,862.00 -14.25 (-0.08%) E-mini Russell 2000 Index Futur
1,980.80 -10.20 (-0.51%) Petróleo
85.20 -0.21 (-0.25%) Oro
2,386.60 +3.60 (+0.15%)
Celldex Therapeutics, Inc. (CLDX)
Fuera de horario:
Celldex Therapeutics, Inc.
Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500
https://www.celldex.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 160
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Anthony S. Marucci M.B.A. | Founder, President, CEO & Director | 1.14M | 3.91M | 1962 |
| Dr. Tibor Keler | Founder, Chief Scientific Officer & Executive VP | 739.03k | 575.74k | 1959 |
| Mr. Sam Martin | Senior VP, CFO, Secretary & Treasurer | 617.26k | 634.9k | 1971 |
| Dr. Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs | 614.12k | N/D | 1957 |
| Dr. Diane C. Young M.D. | Senior VP & Chief Medical Officer | 643.5k | 2.04M | 1957 |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/D | N/D | 1945 |
| Ms. Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration | N/D | N/D | 1975 |
| Patrick Till | Senior Director of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. Freddy A. Jimenez Esq. | Senior VP & General Counsel | 579.7k | N/D | 1969 |
| Dr. Ronald A. Pepin | Chief Business Officer & Senior VP | 441.84k | N/D | 1956 |
Descripción
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de Celldex Therapeutics, Inc. a partir del 1 de abril de 2024 es 1. Las puntuaciones principales son Auditoría: 2; Junta: 2; Derechos del accionista: 1; Compensación: 5.
